PNH Clinical Trial
Official title:
A Retrospective Chart Review Study to Evaluate the Impact of Eculizumab in Korean Paroxysmal Nocturnal Hemoglobinuria Patients
This study is a retrospective chart review study, and the main objective of this study is to identify the impact of eculizumab treatment and the improvement of complications before and after eculizumab treatment, and to evaluate the safety during the treatment and the clinical unmet needs during the treatment in PNH patients in real-world.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04725812 -
Complement Regulation to Undo Systemic Harm in Preeclampsia
|
Phase 2 | |
Completed |
NCT02598583 -
Dose-Escalation Study of ALXN1210 IV in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)
|
Phase 1/Phase 2 | |
Recruiting |
NCT05539248 -
A Study on the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of CAN106 in Subjects With PNH
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03460301 -
Observational of PNH Type Cells in Korean Patients With Bone Marrow Failure Syndrome and Having Hemolytic PNH
|
N/A | |
Completed |
NCT01412047 -
Paroxysmal Nocturnal Hemoglobinuria Human Anti-Human Antibodies Study
|
N/A | |
Completed |
NCT02605993 -
Open-label, Multiple Ascending Dose Study of Ravulizumab (ALXN1210) in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)
|
Phase 2 | |
Completed |
NCT05095168 -
Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of a Single Ascending Dose (SAD) of CAN106 Administered Intravenously (IV) in Healthy Subjects
|
Phase 1 | |
Terminated |
NCT04702568 -
A Long Term Safety Study of BCX9930 in Subjects With Paroxysmal Nocturnal Hemoglobinuria (PNH)
|
Phase 2 | |
Active, not recruiting |
NCT03531255 -
Pegcetacoplan Long Term Safety and Efficacy Extension Study
|
Phase 3 | |
Not yet recruiting |
NCT06449001 -
Study of Danicopan as Add-on Treatment to Ravulizumab or Eculizumab in Pediatric Participants With PNH Who Have Clinically Significant Extravascular Hemolysis
|
Phase 3 | |
Completed |
NCT03593200 -
A Phase IIa Study to Assess the Safety, Efficacy, and Pharmacokinetics of Subcutaneously Administered Pegcetacoplan (APL-2) in Subjects With PNH
|
Phase 2 | |
Completed |
NCT05884060 -
Retrospective Chart Review Screening Algorithm to Assess the Prevalence of PNH-clones
|
||
Available |
NCT05982938 -
Danicopan Early Access Program
|